CTOs on the Move

Hemagen Diagnostics

www.hemagen.com

 
Hemagen Diagnostics is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.hemagen.com
  • 9033 Red Branch Rd
    Columbia, MD USA 21045
  • Phone: 443.367.5500

Executives

Name Title Contact Details

Similar Companies

Amarillo Biosciences

Amarillo Biosciences, Inc. is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Napp Technologies

Napp Technologies is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Pharmaceuticals

Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Medfusion Rx

Medfusion Rx is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspyrian Therapeutics

Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.